Erika Hamilton: Happy to get the word out about the VERITAC2 trial

Erika Hamilton posted on LinkedIn about a recent paper, titled “VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer” published on Future Oncology:

Authors: Erika P Hamilton, Cynthia Ma, Michelino De Laurentiis, Hiroji Iwata, Sara A Hurvitz, Seth A Wander, Michael Danso, Dongrui R Lu, Julia Perkins Smith, Yuan Liu, Lana Tran, Sibyl Anderson, Mario Campone.

“Happy to get the word out about the VERITAC2 trial for patients with HR+ metastatic breast cancer survival model. Post 1st line CDK4/6, novel endocrine therapies are very needed.
Great way to contribute to clinical trials and advancing care.”

Source: Erika Hamilton/LinkedIn

Erika Hamilton is a medical oncologist and the Director of Breast Cancer Program at Sarah Cannon Research Institute (USA). Dr. Hamilton is a past chair of ASCO’s Scientific Breast Committee a ’21-’22, participant of the ASCO Leadership Development Program, Associate Editor for Clinical Breast Cancer, co-chair for Great Debates and Updates in Women’s Oncology Conference and a board member of the Susan G. Komen Foundation of Central Tennessee.

She is active in the community, volunteering with Gilda’s Club Middle Tennessee, the American Cancer Society’s Hope Lodge, Ovarcome ovarian cancer support organization, Brentwood Baptist Church and the Susan G. Komen Race for the Cure.